Recent advances in the therapeutics of psoriatic arthritis (PsA) have provided 
more options to clinicians managing PsA. The purpose of this review is to update 
the reader on treatment options for PsA using conventional synthetic disease 
modifying agents (csDMARDs) and novel therapies including tumour necrosis factor 
alpha inhibitors, interleukin 12/23 inhibitor (ustekinumab), the interleukin 17 
antagonists including secukinumab, brodalumab, ixekizumab, and the 
phosphodiesterase-4 inhibitor, apremilast. Areas covered: We reviewed published 
articles on the treatment of PsA. Our main sources of data included treatment 
recommendations, registry studies, systematic literature reviews, major 
randomised controlled trials for more recently approved drugs, and abstracts 
from the American College of Rheumatology and EULAR meetings. Expert commentary: 
An overview of the evidence for the use of various pharmacotherapeutic agents 
for treatment of this heterogeneous disease was compiled. Treatment options for 
the various domains of PsA are also discussed.